|
| Tuesday, September 24, 2019 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. more info >> |
|
| Friday, September 20, 2019 |
|
|
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan |
| In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide. more info >> |
|
|
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India |
| Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India. more info >> |
|
| Thursday, September 19, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant at World Sleep Congress |
| Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada. more info >> |
|
| Wednesday, September 18, 2019 |
|
|
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019 |
| Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). more info >> |
|
|
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved the combination of LENVIMA, the orally available kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. more info >> |
|
| Tuesday, September 17, 2019 |
|
|
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan |
| Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan. more info >> |
|
| Friday, September 13, 2019 |
|
|
Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease |
| Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). more info >> |
|
| Thursday, August 29, 2019 |
|
|
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action |
| Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide. more info >> |
|
| Wednesday, August 28, 2019 |
|
|
Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan |
| Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods). more info >> |
|
|
|
